top of page
Our Approach
Targeting Cancer with
Breakthrough Therapies
We identify major molecularly driven cancer vulnerabilities where patient need is highest—then we solve them.
Our team has a proven track record of conquering difficult drug discovery challenges that others couldn’t crack, turning previously undruggable targets into precision therapies.
From day one, we prioritize rigorous biological validation and molecularly defined patient populations. We pursue targets with compelling rationale and identified biomarkers that can guide treatment, enabling faster, more capital-efficient trials with a higher probability of clinical success. Where others see intractable chemistry problems, we see the next generation of cancer medicines.
Our experienced in-house team is complemented by longstanding relationships with premier contract research organizations and academic centers, while we maintain full control of all key development decisions and intellectual property without third-party licensing complications.
Molecularly Driven
Precision Therapies
Capital-Efficient Development
Therapeutic Areas
We target aggressive solid tumors with the highest unmet need—cancers where patients have exhausted existing options. Our approach attacks the specific molecular drivers behind each tumor, enabling us to design precision therapies for patients whose cancers have become resistant to current treatments.
Breakthrough Technologies
Our core capability is exceptional drug discovery—and we apply it across multiple modalities. Whether the optimal solution requires small molecules, molecular glues, or novel antibody-drug conjugates, our team has the proven expertise to execute. We’re modality-agnostic and science-driven: each program uses the approach best addressing the underlying biology. As our programs advance into the clinic, we’ll share more details on our pipeline and platforms.
bottom of page